The trajectory of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's unprecedented popularity, generated substantial wealth , the expiry in key territories has introduced considerable volatility. Investors are now grappling with the impact of generic competiti